Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
about
Molecular Connections between Cancer Cell Metabolism and the Tumor MicroenvironmentMolecular markers of paragangliomas/pheochromocytomasRapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cellsA bioassay to measure energy metabolism in mouse colonic crypts, organoids, and sorted stem cellsMetabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.Deciphering the molecular basis of invasiveness in Sdhb-deficient cells.Circulating Metabolites and Survival Among Patients With Pancreatic CancerRole of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.Rethinking pheochromocytomas and paragangliomas from a genomic perspective.Chicken or the egg: Warburg effect and mitochondrial dysfunction.Modifying the maker: Oxygenases target ribosome biology.Effects of Metformin and a Mammalian Target of Rapamycin (mTOR) ATP-Competitive Inhibitor on Targeted Metabolomics in Pancreatic Cancer Cell Line.Emerging applications of metabolomics in drug discovery and precision medicine.Linkage of E2F1 transcriptional network and cell proliferation with respiratory chain activity in breast cancer cells.Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research.The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity.Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors.The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to OncometabolitesRedox-Related Epigenetic Mechanisms in Glioblastoma: Nuclear Factor (Erythroid-Derived 2)-Like 2, Cobalamin, and Dopamine Receptor Subtype 4Metformin targets histone acetylation in cancer-prone epithelial cells.Tumor Microenvironment and Metabolism.Linking CREB function with altered metabolism in murine fibroblast-based model cell lines.Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD.Downregulation of solute carriers of glutamate in gliosomes and synaptosomes may explain local brain metastasis in anaplastic glioblastoma.Oncophosphosignaling Favors a Glycolytic Phenotype in Human Drug Resistant Leukemia.Metabolic Footprints and Molecular Subtypes in Breast Cancer.Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma.New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.Epigenetic regulation of cell fate reprogramming in aging and disease: A predictive computational model.[Metabolome analysis of solid tumors].Cancer research in France.Isocitrate dehydrogenase 1-snail axis dysfunction significantly correlates with breast cancer prognosis and regulates cell invasion ability.Tumour risks and genotype–phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD.Multiple faces of succinate beyond metabolism in bloodThe emerging roles of ribosomal histidyl hydroxylases in cell biology, physiology and disease
P2860
Q28081657-91D27E9E-F691-40AC-BE6F-0ED4529FB17DQ33649025-502CAE08-D189-45FA-801D-0F9A95D74B3AQ33759313-92FF9001-041D-4ECB-9CD6-80B5009B61C2Q35817795-D4E13D3C-E269-43AB-9264-37F533961D5BQ36309665-385C9ACE-9609-4F11-B8B1-DA3975A97182Q36545038-ACC4D79C-C923-4BDC-A32D-6BDE40CEAFA5Q36848069-6593CCAA-41A9-4C60-9BDC-7737A3481FC7Q37701667-37BF5C2A-B88C-4B29-9251-EA78F92B65FFQ38401664-E8D1BF0D-1735-4605-9E13-1266ECEA4595Q38435352-D5BDB8E9-A564-4844-9FB6-EF734C276FC9Q38509463-C85A7B72-F55F-42D9-9913-4095D6C728AEQ38534046-6C75CE91-33B1-4DF1-BDDA-66D14500A7EFQ38700673-26682116-8D7E-4F43-A0DB-FC852E4173B7Q38715697-1F27FBF2-A972-4DC7-9B6A-EE3338143C9CQ38769103-CA0AEDBF-7736-4833-98B9-5B4BE548D66AQ38777012-12C45435-A6D7-413E-A46C-9B19BB91D1EEQ38874166-BFA91AF3-F0ED-4283-9CBA-CDA2D300A813Q38936269-60CAAF1A-58B8-403B-ABDE-37C59DD65A10Q39029921-1A039FFC-690D-4DB2-8D30-F8C5574B3680Q39129064-79DAA630-1468-492B-9694-83C0AD787EB8Q39205930-BF21E895-2BCF-4E26-8185-1FD210D89B5FQ41037176-7740B260-8404-4B50-93A7-7F2A094A5343Q42293431-D1DFB888-8EDC-4955-8632-B727CBA31CE4Q42983569-49BA07A8-C070-4F38-9FED-C25EDFC8356BQ47169336-91E7D501-E64F-4033-9E46-9E279ABB9F5DQ47306639-BCDEAADD-11B7-4556-B23B-E8E1D16799A0Q47550829-94790EC0-D8F5-4457-9D4A-C65760A5718EQ48208799-1C51E870-57C6-421D-94DE-55E340514580Q48306335-930FF08E-A669-4103-9FEC-15D6DF3647D5Q49871101-8A2078D0-E29F-4FA5-B91E-38EACDF9477CQ49948832-B4FDB19F-3603-43EF-8B9E-1784994F2D07Q50229413-C97D5251-4B62-4E8C-A5D0-EBB2A3867DE0Q51556720-EC4BEC3D-3B41-421F-8425-198093EEDA72Q51806041-4ED65641-2601-4B14-8FB1-A92361B331E1Q53232370-A943FDFE-0C2A-4F1C-9CBC-C446AACBE262Q54981076-6EE19F9A-CA41-43E4-ADF0-0B89571171F2Q55361669-58D6E730-2B4A-4A56-BB8D-E55A9CAD57D6Q57139150-C9820EEC-8D1A-48AD-8D20-CA11808708BBQ58700015-57DA5861-9FB1-4203-A3A5-8FF925943831
P2860
Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
@en
type
label
Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
@en
prefLabel
Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
@en
P2860
P50
P356
P1476
Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
@en
P2093
Aurélie Morin
P2860
P304
P356
10.1002/IJC.29080
P577
2014-08-14T00:00:00Z